Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer
Valeria Quaranta(University of Liverpool), Michael C. Schmid(University of Liverpool), Ainhoa Mielgo(University of Liverpool), Daniel H. Palmer(University of Liverpool), Carolyn Rainer(University of Liverpool), Sebastian R. Nielsen(Icahn School of Medicine at Mount Sinai), Arthur Taylor(Leibniz Institute for Solid State and Materials Research), Meirion Raymant(University of Liverpool), Muhammad S. Ahmed(University of Liverpool), Dannielle D. Engle(Cold Spring Harbor Laboratory), David A. Tuveson(Cold Spring Harbor Laboratory), Fiona Campbell(University of Birmingham)
Cited by 164
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
|The Journal of Experimental Medicine|2017|2.4k